ArticleCureus2024

Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.

Mehul Bhattacharyya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.